India’s Rare-Disease Drug Sector: Turning Pharma Strength into Affordable Innovation
Context
India’s pharmaceutical capabilities and large, diverse patient population create an opportunity to expand research and manufacturing of medicines for rare diseases.
Why Rare-Disease Drug Development Matters
Rare-disease treatments are often extremely expensive because companies must recover substantial research and development costs from a small patient population. Medicines developed specifically for such conditions are commonly called orphan drugs.
Domestic development and manufacturing could:
- Reduce dependence on costly imported therapies.
- Improve access to advanced treatments for Indian patients.
- Utilise India’s expertise in generics, biosimilars and emerging therapies.
- Create opportunities for clinical research based on India’s large and genetically diverse population.
- Strengthen specialised pharmaceutical exports and global competitiveness.
- Generate investment and skilled employment in biotechnology and advanced manufacturing.
India’s Opportunity
India possesses several advantages that could support an orphan-drug ecosystem. Its large patient population can facilitate clinical research, while disease registries can help identify eligible participants and understand disease patterns.
The country’s established pharmaceutical manufacturing base also provides a foundation for small-batch production, biosimilars and advanced therapies. Collaboration with international pharmaceutical companies and research institutions could further enable technology transfer and local production of existing orphan drugs.
Major Challenges
High R&D Costs
Drug discovery and clinical trials require substantial investment despite the limited number of potential patients.
Limited Commercial Viability
Small markets and uncertain demand can discourage private investment in orphan-drug development.
Extremely High Treatment Costs
Advanced treatments, particularly gene therapies, can cost several crores of rupees, placing them beyond the reach of many families.
Clinical-Trial Difficulties
Identifying suitable patients, maintaining reliable disease registries and establishing appropriate trial endpoints remain challenging.
Limited Therapeutic Options
Many rare diseases still do not have specific approved treatments.
Regulatory Hurdles
Complex or lengthy approval processes can delay the availability of potentially useful medicines.
Manufacturing Constraints
Specialised infrastructure, stringent quality control and small-scale production can increase manufacturing costs.
Limited Financial Protection
Inadequate insurance coverage can leave patients dependent on crowdfunding and other financial assistance.
Existing Policy Support
National Policy for Rare Diseases, 2021
The policy provides financial assistance of up to ₹50 lakh per eligible patient for specified treatments through designated Centres of Excellence.
Centres of Excellence
These institutions support specialised diagnosis and treatment while also contributing to research and coordination of rare-disease services.
New Drugs and Clinical Trials Rules, 2019
Rule 101 provides a mechanism through which certain drugs approved in specified countries can be considered for approval in India without necessarily repeating clinical trials, subject to applicable regulatory requirements.
Government Crowdfunding Support
Government-supported crowdfunding mechanisms enable eligible patients to mobilise additional financial assistance for expensive treatments.
International Experience
Frameworks such as the U.S. Orphan Drug Act, 1983 use measures including tax incentives, grants and market exclusivity to encourage orphan-drug research and development.
Way Forward
Streamline Regulatory Processes
Create transparent and predictable approval pathways while maintaining rigorous standards for safety, efficacy and quality.
Provide Financial Incentives
Use tax benefits, research grants and appropriate production incentives to encourage investment in orphan-drug development.
Strengthen Clinical Research
Expand patient registries and promote collaboration among pharmaceutical companies, hospitals and research institutions.
Promote Public-Private Partnerships
Encourage international companies to establish research and development facilities in India and facilitate technology transfer to domestic manufacturers.
Ensure Affordable Access
Government procurement and advance market commitments can create predictable demand while helping reduce treatment costs.
Strengthen Domestic Manufacturing
Support specialised infrastructure and high-quality small-batch production of orphan drugs and advanced therapies.
Promote International Collaboration
Joint research, clinical trials and technology transfer can help integrate India into the global rare-disease drug ecosystem.
Conclusion
India can build on its pharmaceutical strengths to develop a competitive rare-disease drug ecosystem. The key objective should be to ensure that pharmaceutical innovation translates into affordable, accessible and equitable treatment for patients with rare diseases.
Source : The Hindu